Compare Cytokinetics Inc (CYTK) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs RLX Technology Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: Cytokinetics Inc is far larger — about 4.4× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | RLX | |
|---|---|---|
Market Cap | $10.63B | $2.42B |
Sector | Technology | Technology |
52-Week High | $87.26 | $2.73 |
52-Week Low | $35.33 | $1.79 |
Enterprise Value | $10.74B | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
RLX Technology trades at $2.02, up 1.0% today, amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 22.47% net margins and solid cash flow generation, though recent quarterly earnings have missed expectations. International expansion remains a key growth driver, with overseas revenue now exceeding 70% of total sales following the Totally Wicked acquisition.
While RLX maintains strong fundamentals and cash reserves, the bearish technical outlook and recent earnings misses create near-term uncertainty. The company's international growth strategy offers potential upside, but regulatory risks in the vaping industry and execution challenges pose significant headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
